# Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML

> **NCT01191801** · PHASE3 · COMPLETED · sponsor: **Sunesis Pharmaceuticals** · enrollment: 711 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** vosaroxin + cytarabine
- **DRUG:** placebo + cytarabine

## Key facts

- **NCT ID:** NCT01191801
- **Lead sponsor:** Sunesis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-17
- **Primary completion:** 2014-09-26
- **Final completion:** 2017-03-01
- **Target enrollment:** 711 (ACTUAL)
- **Last updated:** 2018-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01191801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01191801, "Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01191801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*